摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(2,4-dimethoxyphenyl)methyl-(4-hydroxy-3-methylbutan-2-yl)carbamoyl]oxyethyl 5-[(3R)-dithiolan-3-yl]pentanoate | 1334670-58-4

中文名称
——
中文别名
——
英文名称
1-[(2,4-dimethoxyphenyl)methyl-(4-hydroxy-3-methylbutan-2-yl)carbamoyl]oxyethyl 5-[(3R)-dithiolan-3-yl]pentanoate
英文别名
——
1-[(2,4-dimethoxyphenyl)methyl-(4-hydroxy-3-methylbutan-2-yl)carbamoyl]oxyethyl 5-[(3R)-dithiolan-3-yl]pentanoate化学式
CAS
1334670-58-4
化学式
C25H39NO7S2
mdl
——
分子量
529.719
InChiKey
OJOBCNLDHGXAKL-NYCJEKGVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    35
  • 可旋转键数:
    16
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.68
  • 拓扑面积:
    145
  • 氢给体数:
    1
  • 氢受体数:
    9

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • COMPOUND AND METHOD FOR THE TREATMENT OF PAIN
    申请人:KANDULA MAHESH
    公开号:US20110237658A1
    公开(公告)日:2011-09-29
    The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications.
    本公开提供了一种化合物的化学式1。本公开还提供了一种合成该化合物的方法。化学式1的化合物或其药用可接受的盐,以及其多晶型、溶剂合物和水合物可以制成药物组合物。化学式1的药物组合物或最终化合物可以制成用于非侵入性口服、局部(例如经皮)、肠内、经粘膜、靶向递送、持续释放递送、延迟释放、脉冲释放和静脉途径的方法。这些组合物可用于治疗伴随慢性疾病或其相关并发症表现的慢性疼痛。
  • [EN] COMPOUND AND METHOD FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉ ET PROCÉDÉ POUR LE TRAITEMENT DE LA DOULEUR
    申请人:KANDULA MAHESH
    公开号:WO2011117749A1
    公开(公告)日:2011-09-29
    The disclosure herein provides a compound of formula (1). The disclosure also provides a method of synthesizing the compound of formula (1). The compound of formula (1) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof.may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula (1) or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications.
  • [EN] DITHIOLAN-3-YLPENTANOATE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN<br/>[FR] DÉRIVÉS DE DITHIOLAN-3-YLPENTANOATE, COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES DE TRAITEMENT DE LA DOULEUR
    申请人:KRISANI BIOSCIENCES P LTD
    公开号:WO2015118554A1
    公开(公告)日:2015-08-13
    The disclosure herein provides 1-carbamoyloxyethyl 5-(1,2-dithiolan-3-yl)pentanoate derivatives of formula I, formula II and formula III. The disclosure also provides a method of synthesizing the compound of formula I, formula II and formula III. The compound of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates, thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula I, formula II and formula III or the final compound of formula I, formula II or formula III may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications.
    本公开提供了式I、式II和式III的1-羰胺氧乙基5-(1,2-二硫代环戊烷-3-基)戊酸酯衍生物。本公开还提供了一种合成式I、式II和式III化合物的方法。式I、式II和式III化合物或其药用可接受的盐,以及其多晶型、溶剂合物和水合物,可制成药物组合物。式I、式II和式III化合物的药物组合物或式I、式II或式III的最终化合物可制成用于非侵入性口服、局部(例如经皮)、肠内、经粘膜、靶向递送、持续释放递送、延迟释放、脉冲释放和静脉途径的方法。这种组合物可用于治疗伴随慢性疾病或其相关并发症表现的慢性疼痛。
查看更多

同类化合物

螺[二环[2.2.1]庚烷-2,2'-[1,3]二噁戊环]-5-乙醇,(1S,4R,5R)- 芦笋酸 硫辛酸钠 硫辛酸氨基丁三醇盐 硫辛酸杂质D 硫辛酸杂质9 硫辛酸乙酯 甲基沙蚕毒素 沙蚕毒素 氨基乙醛乙烷二硫代缩醛 左旋硫辛酸 呋喃-2-甲醛乙烷-1,2-二基二硫代缩醛 二乙基硫辛酰胺 三硫代碳酸乙烯酯 rac-α-硫辛酸-d5 R-(alpha)-硫辛酸氨基丁三醇盐 R-(+)-硫辛酸 N-(1,3-二噻戊环-2-亚基氨基)乙酰胺 N-(1,3-二噻戊环-2-亚基氨基)-2-氧代丙酰胺 DL-α-硫辛酸-NHS 5-[(3R)-二噻戊环-3-基]戊酸;2-羟基丙酸 4-甲基二噻戊环-3-酮 4-甲基-1,3-二硫醇-2-酮 4-甲基-1,3-二噻戊环-2-亚胺盐酸盐 4-甲基-1,2-噻吩-4-羧酸 4-甲基-1,2-二噻吩-4-羧胺 4-乙基-1,3-二噻戊环-2-硫酮 4-[[5-(1,2-二噻戊环-3-基)-1-氧代戊基]氨基]丁酸 4-[(苯基硫基)甲基]苯甲酸 4,5-二甲基-2-[2-(甲硫基)乙基]-1,3-二噻戊环 2-甲基-1,3-二硫戊环 2-己基-1,3-二噻戊环 2-亚甲基-1,3-二硫杂环戊烷 2-(氯甲基)-1,3-二噻戊环 2-(三氯甲基)-1,3-二噻戊环 2-(2-噻吩基)-1,3-二噻戊环 2-(2,4-环戊二烯-1-亚基)-1,3-二硫戊环 2-(1,3-二噻戊环-2-基)-1,3-二噻戊环 2-(1,2-二硫烷-3-基)乙酸 2,4-二氯-6,7-二硫杂双环[3.2.1]辛烷 2,3-二硫杂螺[4.4]壬烷 2,3,7,8-四硫杂螺[4.4]壬烷 2,2'-[1,2-乙烷二基二(硫代)]二[2-(三氟甲基)-1,3-二噻戊环] 1,‐2-二硫戊基-4-醇 1,4,6,9-四硫杂螺[4.4]壬烷 1,3-二硫烷-2-甲酸乙酯 1,3-二硫代环-1,1,3,3-四氧 1,3-二硫代坊 1,3-二噻戊环-4-羧酸 1,3-二噻戊环-2-羧酸